Prescribing information

 

 

What is REVOLADE?

 

REVOLADE is a thrombopoietin receptor agonist or TPO-RA with a targeted mechanism of action that increases platelet production without compromising the immune system1–3

REVOLADE is a once-daily oral treatment for primary immune thrombocytopenia (ITP) patients aged 1 year and over who are refractory to other treatments. It is available as a film-coated tablet (FCT) or a powder for oral suspension (PfOS) for those who have trouble swallowing a tablet1,2

 

What can REVOLADE offer your ITP patients?

target icon

TARGETED

green line separator

Platelet control without immunosuppression1–3

Learn more

tested icon

TESTED

green line separator

Across 5 clinical trials4–8
In over 5000 global subjects9*

Learn more

trusted icon

TRUSTED

green line separator

10 years of real-world
clinical practice1

Learn more

 

 

Choose REVOLADE for your ITP patients with confidence

 

FCT, film-coated tablet; ITP, immune thrombocytopenia; PfOS, powder for oral suspension; TPO-RA, thrombopoietin receptor agonist.

 

*A total of 5541 subjects have been exposed to REVOLADE since the development international birthdate in October of 2004.9

 

References

  1. REVOLADE FCT Summary of Product Characteristics.
  2. REVOLADE PfOS Summary of Product Characteristics.
  3. Kuter D. Int J Hematol. 2013;98:10–23.
  4. Wong R, et al. Blood. 2017;130:2527–2536.
  5. Cheng G, et al. Lancet. 2011;377:393–402.
  6. Bussel J, et al. Br J Haematol. 2013;160:538–546.
  7. Bussel J, et al. Lancet. 2015;2:315–325.
  8. Grainger J, et al. Lancet. 2015;386:1649–1658.
  9. Data on file REVDOFPATIENTYEARS.
Rate this content: 
No votes yet
UK | June 2021 | 125330
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com